...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >Dupilumab improves health‐related quality of life in patients with chronic rhinosinusitis with nasal polyposis
【24h】

Dupilumab improves health‐related quality of life in patients with chronic rhinosinusitis with nasal polyposis

机译：Dupilumab在患有鼻息肉炎患者患者中提高了与慢性鼻炎患者的健康状生活质量

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Background Chronic rhinosinusitis with nasal polyposis (CRSwNP) negatively affects health‐related quality of life (HRQoL). In a previously reported randomized clinical trial (NCT01920893), addition of dupilumab to mometasone furoate in patients with CRSwNP refractory to intranasal corticosteroids (INCS) significantly improved endoscopic, radiographic, and clinical endpoints and patient‐reported outcomes. The objective of this analysis was to examine the impact of dupilumab treatment on HRQoL and productivity using secondary outcome data from this trial. Methods Following a 4‐week mometasone furoate nasal spray run‐in, patients were randomized to commence subcutaneous dupilumab (600?mg loading dose, then 300?mg once weekly for 15?weeks [n?=?30], or matched placebo [n?=?30]). Outcomes included scores on the CRS disease severity visual analog scale (VAS), 22‐item Sino‐Nasal Outcome Test (SNOT‐22), 5‐dimension EuroQoL (EQ‐5D) general health status VAS, and 36‐item Short‐Form Health Survey (SF‐36) for HRQoL and nasal polyp‐related healthcare resource use questionnaires. Results Following 16?weeks of treatment, the proportion of patients with moderate‐to‐severe CRSwNP (VAS??3‐10) decreased from 86.2% to 21.4% with dupilumab and 88.0% to 84.2% with placebo. Dupilumab (vs placebo) resulted in significantly greater improvement in HRQoL, based on SNOT‐22, SF‐36, and EQ‐5D VAS scores. The dupilumab group had a significantly lower adjusted annualized mean number of sick leave days (0.09, vs 4.18 with placebo, P ?=?.015) and significantly greater improvement (vs placebo) in the SNOT‐22 item “reduced productivity.” Conclusions In adults with CRSwNP refractory to treatment with INCS alone, the addition of dupilumab reduced disease severity, significantly improved HRQoL, and improved productivity.
机译：摘要背景慢性鼻素炎与鼻息肉（CRSWNP）产生负面影响与健康相关的生命质量（HRQOL）。在先前报道的随机临床试验（NCT01920893）中，向患有CRSWNP难治的患者中加入杜帕里姆的呋喃酸盐，对鼻内皮质类固醇（INCS）显着改善内窥镜，射线照相和临床终点和患者报告的结果。该分析的目的是使用来自该试验的二次结果数据来检查杜帕里姆人治疗对HRQOL和生产率的影响。方法后4周的莫替斯呋喃鼻腔喷射液体，患者随机开始，以开始皮下杜松岛（600×Mg加载剂量，然后每周300毫克，每周300？周[N？=？30]，或匹配的安慰剂[ n？=？30]）。结果包括CRS疾病严重程度的分数视觉模拟规模（VAS），22项中鼻态结果测试（SNOT-22），5维欧QOL（EQ-5D）一般健康状况VAS，以及36项短型HRQOL和鼻息肉相关医疗资源使用问卷的健康调查（SF-36）。结果在16次治疗后，中度至严重的CRSWNP（VAS？＆β3-10）的患者的比例从杜帕里米布的86.2％降至21.4％，安慰剂的88.0％至84.2％。基于Snot-22，SF-36和EQ-5D VAS分数，Hrqol导致HRQOL的改善导致Dupilumab（VS Placebo）产生显着更大。 Dupilumab组的调整后的年化平均数量显着降低（0.09，与安慰剂，P？= 015），并在Snot-22项目中显着提高了更大的改进（VS安慰剂）“降低了生产力”。结论在CRSMNP难治性与INCS治疗中的成人单独治疗，增加杜帕里姆为疾病严重程度，显着改善的HRQOL，提高生产率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号